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The isradipine is the potent anti hypertensive drug, which is matrix in polymeric nanoparticle
by using solvent evaporation method. In this work, 3-factor, 3-level Box-Behnken design was
used to optimize the process parameters like polymer concentration (A), sonication frequency
(B) and sonication time (C). Three dependent variable’s particle size, entrapment efficiency
and practical yield were measured as responses. Mathematical equations and response sur-
face plots were used to relate the dependent and independent variables. The optimization
model of particle size of 343.14 nm, entrapment efficiency of about 83.74% and practical yield
of 85.39% with A, B and C levels of 750 mg, 37.5 min and 40 kHz respectively. The observed
responses were in close agreement with the predicted values of the optimized process. The
prepared nanoparticle was characterized by Fourier transform infrared spectroscopy, mor-
phological studies and in-vitro drug release studies. The prepared nanoparticle was showed
good sustained release of drug upto 24 h. The anti-hypertensive study was performed on
animal model. The PMMA (Poly-Methyl-Metha- Acrylate) isradipine nano particle shows fall
in blood pressure was delayed and reach 15272 mmHg at 1 h. The actionwas sustained until
prolong period. Based on pharmacokinetic and pharmacodynamics parameter, the isradipine
nanoparticles shows better bioavailability compare with solution form.
& 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nanoparticles are very small particle's diameter a range is between 100 and 1000 nm [1]. Nanotechnological research is
currently applied in various field likes biomedical, electronic and optical [2]. The nano research was initiated in 9th century
at mesopotaomia. The artisans used to generate a glittering effect on the surface of pots [3]. Now it is explored by the entire
field in worldwide. The use of nanoparticle in biology and medicine including fluorescent biological markers for diagnose of
diseases [4] and drug delivery system for all the complicated diseases including genetic diseases. The nanoparticles are
being ample use in drug delivery system due to their properties like size, surface characteristics of nanoparticles and its easy
adaptability for both active and passive targeting. These particles can be used to control and sustain the release of the drug
during the transportation as well as targeted release. These can increase the drug therapeutic efficacy by altering dis-
tribution and clearance with significant reduction in side effects [5].an open access article under the CC BY-NC-ND license
.
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coronary, cerebral and skeletal muscle vasculature. Isradipine is a water insoluble calcium channel blocker approved for the
treatment of angina pectoris and hypertension. It undergoes significant first-pass metabolism and possess low oral
bio-availability (15–24%). The elimination of isradipine is biphasic with an early half-life of 1½2 h, and a terminal half-life
of about 8 h. The total body clearance of isradipine is 1.4 L/min and the apparent volume of distribution is 3 L/kg [6].
In this present study, isradipine nanoparticle formula optimized by factorial design software. The optimized formula is
subjected to scale up process. Isradipine is low bioavailable, high protein binding and fast elimination molecule. The
bioavailability and therapeutic efficacy could be improved by sustained release formulations. In these research isradipine
nanoparticles preparation was applied box behnken design model to obtain the optimal formula.2. Materials and methods
The isradipine was obtained from Sigma Aldrich, USA. PMMA (Poly-Methyl-Metha- Acrylate) was obtained from KLH
chemicals, Malaysia. Poloxamer 407 and ethanol were purchased from Suka chemicals, SDN BHD, Malaysia. All other
chemicals and solvents used were of analytical grade.2.1. Factorial design for formulation of isradipine nanoparticle
Initially, preliminary experiments were performed to determine the main factors and the appropriate ranges in which the
optimum range lie. The effects of the three factors (polymer concentration, sonication frequency and sonication time) on the
particle size, entrapment efficiency and practical yield were tested. Through preliminary screening the polymer concentration,
sonication frequency and sonication time were identified as the most significant variables within the range of 300–1200 mg,
20–60 kHz, 15–60 min, respectively. On the basis of the preliminary trials a 3-factor, 3-level Box-Behnken design [7–9] was
employed to study the effect of each independent variable on dependent variables (particle size, entrapment efficiency and
practical yield). This design is suitable for exploring quadratic response surfaces and constructing second-order polynomial
models. The design consists of replicated centre points and the set of points lying at the midpoint of each edge of the mul-
tidimensional cube that defines the region of interest. The independent factors and the dependent variables used in the design
are listed in Table 1. The experiments were conducted as for the design of experiments and the responses for the dependent
variables were in Table 2. The response surface of the variables inside the experimental domain was analyzed using Stat-Ease
design expert software. Subsequently, three additional confirmation experiments were conducted to verify the validity of the
statistical experimental strategy.2.2. Preparation of nanoparticle
The isradipine nanoparticle was prepared by solvent evaporation method [10]. The required quantity of isradipine was
dissolved in ethanol and the required quantities of polymer PMMA (Poly-Metha-Methyl-Acrylates) was dissolved in di-
chloromethane. The drug–polymer mixture was added drop wise into 2% poloxamer 407 solution (2 g of poloxamer dis-
solved in 100 mL of distilled water) as a quasiemulsifier under ultra probe sonication at 20–60 kHz frequency for various
time intervals. To complete the precipitation process, 200 mL of water was added and mixed with magnetic stirrer for 12 h.
Organic solvent was completely removed by using Rotoevaporator at 40 °C for 30 min. The formed nanoparticles suspension
was freeze dried under 20 °C for 26 h to get free flowing powder of nanoparticles.Table 1
List of dependent and independent variables in Box-Behnken design for isradipine nanoparticle.
Factor Name Units Minimum Maximum
A Polymer mg 300 1200
B Sonication time min 15 60
C Sonication frequency kHz 20 60
Response Name Units
R1 Particle size nm
R2 Entrapment efficiency %
R3 Practical yield %
Table 2
Central composite design with observed responses.
Run Factor 1 Factor 2 Factor 3 Response Y1 Response Y2 Response Y3
A: Polymer B: Sonication time C: Sonication Frequency Particle size Entrapment efficiency Practical yield
mg min kHz nm % %
1 750 37.5 40 352.12 86.42 86.3
2 750 15 20 354.24 84.22 86.4
3 750 60 20 350.4 86.06 86.6
4 300 15 40 356.62 86.42 88.64
5 300 37.5 60 356.46 78.62 88.12
6 300 60 40 358.26 89.48 88.64
7 1200 37.5 20 367.34 86.34 78.6
8 300 37.5 20 352.42 72.64 88.24
9 750 15 60 351.24 80.64 86.24
10 1200 60 40 360.12 82.64 72.4
11 750 37.5 40 352.46 86.04 86.82
12 750 37.5 40 354.22 86.4 86.42
13 750 37.5 40 356.42 82.54 81.25
14 1200 15 40 261.42 84.64 85.02
15 1200 37.5 60 251.4 85.06 88.32
16 750 37.5 40 356.12 86.32 87.02
17 750 37.5 40 342.14 83.62 86.74
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2.3.1. Particle size
Nanoparticles size was determined by using a Zetasizer 300 HS (Malvern Instruments, UK). About 2 mg of samples were
dispersed in 2 mL of distilled water and measured the particle size at a temperature of 25 °C. The diameter was calculated
from the autocorrelation function of intensity of light scattered from nanoparticles. The values were measured in triplicate.
2.3.2. Entrapment efficiency (EE %)
Entrapment efficiency was calculated by measuring the quantity of the entrapped drug. The drug samples were analyzed
by RP-HPLC (Reverse Phase High Performance Liquid Chromatography) method at 325 nm, which was obtained after ul-
tracentrifugation of nanoparticles suspension [11]. The EE was calculated by using the following formula:






where W1 is weight of entrapped drugs, W2 is the total weight of drugs used.
2.3.3. Morphology of nanoparticles
Morphology of isradipine nanoparticles was observed by scanning electron microscope. A little quantity of nanoparticles
sample was spread on a metal stub. The stub was coated with conductive gold by Hitachi 1010 ion sputter and observed
under Hitachi 3000N scanning electron microscope (JSM 5610 LV SEM, JEOL, Japan) chamber. The image was snapped at an
acceleration voltage of 20 kV with a chamber pressure of 0.6 mmHg.
2.3.4. Compatibility studies
The isradipine and PMMA compatibility was analyzed by FTIR spectroscopy. The dry nanoparticle power was mixed with
100 mg of potassium bromide (KBr). The sample was compressed to disc by applying pressure of 5 t for 3 min in a hydraulic
press. The prepared pellet was placed in the sample cell and the spectrums were analyzed in the region of 4000–400 cm1.
By comparing the spectrums of drug and drug loaded nanoparticle, the compatibility study was performed.
2.3.5. In-vitro release study
In-vitro release study of nanoparticle was carried out by using modified Franz diffusion apparatus at 3772 °C. About
50 mg drug equivalent nanoparticles were suspended in donor compartment containing phosphate buffer (pH 7.4). Drug
release was assessed by intermittently sampling 5 mL of phosphate buffer as receptor medium and fresh buffer saline pH
7.4 was replaced. The samples were filtered with membrane filter (0.22 μ) and the amount of drug released was quantified
by a RP-HPLC method at 325 nm [12].
2.3.6. In-vivo evaluation studies
2.3.6.1. Preparation of animals. Adult male spontaneously hypertensive rats (SHR) were allowed one week to adapt the
environmental conditions before all experiments. They were 11–12 weeks old and weighed 220720 g when experiments
were performed.
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nanoparticle loaded isradipine and plain nanoparticle). The dosing volume was 5 mL/kg and there were 6 SH (Sponta-
neously Hypertensive) rats per group. Measurements of rat systolic arterial blood pressure were fasted for 15 h before and
during the experiments; water was given ad libitum. Systolic arterial blood pressure was measured by tail plethysmography
at 0, 15 min, 0.5, 1, 2, 4, 8 and 12 h following oral administration of nanoparticles.
2.3.6.3. Blood sampling. The common carotid artery of separate groups of rat was cannulated under halothane anaesthesia
[13]. The cannula was labelled with a solution containing poly vinylpyrrolidone (PVP) (0.5 mg/mL), heparine (200 i. u/mL),
sodium chloride (90 mg/mL) and methylene blue. A minute quantity of methylene blue (51 mg/L) was added in order to
give a blue colour to the solution used to label the cannula. In this way any leak from the cannula could easily be detected.
The cannula was sealed and rats were housed in individual cages. Experiments were performed 15 h later. Blood samples
were withdrawn at 0, 15 min, 0.5, 1, 2, 4, 8, 10 and 12 h after oral administration of each dosage form (Pure isradipine,
PMMA nanoparticle loaded isradipine & plain nanoparticle). Blood samples were centrifuged at 1500g for 10 min at 48 °C
and the plasma samples were analyzed immediately by RP-HPLC.
2.3.6.4. Analytical methods. Reversed phase HPLC method was chosen for isradipine. HPLC chromatographic separation
was performed on a shimadzu liquid chromatographic system equipped with a LC-20CE solvent delivery system
(pump), SPD-20A photo diode array detector, and SIL-20ACHT injector. LC solution version 1.25 was applied for data
collecting and processing (Shimadzu, Japan). Isradipine plasma samples (100 mL), 4 mL of a dichloromethane: n
hexane mixture (3: 7, v/v) and 1 mL of distilled water were mixed in a light-proof test tube. The mixture was shaken
for 15 min with a rotary agitator and centrifuged for 5 min at 1500g. Three millilitres of the supernatant were
transferred to a light-proof reaction. The residue was dissolved in 200 mL of the mobile phase containing n-butyl
p-aminobenzoate (butamben) as internal standard (500 mg/mL). 05 mM ammonium acetate buffer (pH 4.5) and
acetonitrile at a ratio of 30:70% v/v was used as the mobile phase with the flow rate of 1.0 mL/min. Reversed phase
thermos C18 column was used as the stationary phase. The flowrate was 1.0 mL/min and the detection wavelength of
isradipine was 325 nm.
2.3.6.5. Statistical analysis. Analysis of variance (ANOVA) and linear regression analysis were performed on the blood
pressure and plasma isradipine data. Means were compared with the Bonferroni test. Differences were considered sig-
nificant at Po0.05.3. Results and discussion
3.1. Optimization process variables of isradipine nanoparticles
The most widely used method for the synthesis of the nanoparticle is the solvent evaporation method; potential ad-
vantages of this technique in the synthesis of biodegradable materials include the acceleration of nanoparticle formation,
improved product selectivity, narrow particle size distribution and high yield. In this work, we report the first successful
result on the preparation of isradipine nanoparticle. Through preliminary experiments the polymer concentration (A), so-
nication frequency (B) and sonication time(C) were identified as the most significant variables influence the particle size,
entrapment efficiency and practical yield.
Design of experiments (DOE) has been used as a powerful approach to reduce the variation in a process and, ultimately,
to produce high product yield with uniform particle size distribution. Among various design approaches, the Box-Behnken
design was used to optimize and evaluate main effects, interaction effects and quadratic effects of the process variables on
the particle size, entrapment efficiency and practical yield. This design is suitable for exploring quadratic response surfacesTable 3
ANOVA results of the quadratic model for the response particle size (Y1).
Sources of variations Sum of squares df Mean square F value p-Value Prob 4F R2
Model 13019.88 6 2169.98 4.82 0.0145 Significant
A - Polymer 4208.11 1 4208.11 9.35 0.0121
B - Sonication time 954.85 1 954.85 2.12 0.1759
C - Sonication Frequency 1896.05 1 1896.05 4.21 0.0672
AB 2355.16 1 2355.16 5.23 0.0452
AC 3598.80 1 3598.80 8.00 0.0179
BC 6.92 1 6.92 0.015 0.9038
Residual 4499.96 10 450.00
Lack of Fit 4484.02 6 747.34 187.47 o0.0001 Significant
Table 4
ANOVA results of the quadratic model for the response Entrapment efficiency (Y2).
Sources of variations Sum of squares df Mean square F value p-Value Prob 4F R2
Model 0.000 0
Residual 241.76 16 15.11
Lack of Fit 230.38 12 19.20 6.75 0.0397 Significant
Table 5
ANOVA results of the quadratic model for the response Practical yield (Y3).
Sources of variations Sum of squares df Mean square F value p-Value Prob 4F R2
Model 136.54 3 45.51 3.88 0.0350 Significant
A - Polymer 107.31 1 107.31 9.15 0.0098
B - Sonication time 17.76 1 17.76 1.51 0.2403
C - Sonication Frequency 11.47 1 11.47 0.98 0.3407
Residual 152.48 13 11.73
Lack of Fit 128.90 9 14.32 2.43 0.2037 Significant
Fig. 1. Perturbation plot showing the main effect of Polymer concentration (A), Sonication frequency (B) and sonication time (C) on Particle size (Y1).
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at the midpoint of each edge of the multidimensional cube. These designs are rotatable (or near rotatable) and require
3 levels of each factor.
Seventeen experiments were required for the response surface methodology based on the Box-Behnken design. Based on
the experimental design, the factor combinations yielded different responses as presented in Table 1. These results clearly
indicate that all the dependent variables are strongly dependent on the selected independent variables as they show a wide
variation among the 17 batches (Table 2). Data were analyzed using Stat-Ease Design Expert software to obtain analysis of
variance (ANOVA), regression coefficients and regression equation. Mathematical relationship generated using multiple
linear regression analysis for the studied variables are expressed. These equations represent the quantitative effect of
polymer concentration (A), sonication frequency (B) and sonication time(C) and their interaction on particle size (Y1),
entrapment efficiency (Y2) and practical yield (Y3). The values of the coefficient A, B and C are related to the effect of these
variables on the responses Y1, Y2 and Y3. Coefficients with more than one factor term and those with higher order terms
Fig. 2. Response surface plot presenting the interaction between the Polymer and Sonication time affecting the particle size at constant sonication
frequency.
Fig. 3. Factorial contour Response surface plot presenting the interaction between the Polymer and Sonication time affecting the particle size at constant
sonication frequency.
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negative sign indicates an antagonistic effect. A backward elimination procedure was adopted to fit the data to the quadratic
model. All the polynomial equations were found to be statistically significant (P o 0.014), as determined using ANOVA
(Tables 3–5), as per the provision of design expert software. The mathematical model generated for practical yield (Y1) was
found to be significant with F-value of 4.82 (p o0.0005) and R2 value of 0.9942. The independent variables A, B, C and the
quadratic term of AB, AC and BC have significant effects on the particle size, since the P-values less than 0.05 represent the
significant model terms as shown in Table 3. Results of the equation indicate that the effect of A is more significant than B and C.
Fig. 4. Cubic design presenting the interaction between the Polymer and Sonication time and sonication frequency affecting the Particle size.
Fig. 5. Perturbation plot showing the main effect of Polymer concentration (A), Sonication frequency (B) and sonication time (C) on entrapment efficiency
(Y2).
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using the perturbation and 3D response surface plots. The perturbation plot (Fig. 1) showing the main effects of A, B and C
on the particle size (Y1) of nanoparticle. This figure clearly shows that A has the main and the major effect on Y1 followed by
B which has a moderate effect on Y1 followed by C which has a little effect on Y1. The relationship between the dependent
and independent variables was further elucidated using response surface plots in Fig. 2. Figs. 3 and 4 shows the interactive
effect of A and B on the particle size (Y1) at fixed level of C. At low levels of A (polymer concentration), Y1 increases from
Fig. 6. Factorial contour Response surface plot presenting the interaction between the Polymer and Sonication time affecting the Entrapment efficiency at
constant sonication frequency.
Fig. 7. Response surface plot presenting the interaction between the Polymer and Sonication time affecting the Entrapment efficiency at constant soni-
cation frequency.
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was found to be in the range of 251–367 nm as shown in Table 2. The factorial equation for particle size exhibited a good
correlation coefficient (1.000) and the model F value of 187.47 which implies the model is significant. Values of “Prob 4 F”
less than 0.0500 indicate model terms are significant. All the three variables having the negative effect on the particle size,
which means these factors, are inversely proportional to the response. The influence of the main and interactive effects of
independent variables on the particle size was further elucidated using the perturbation and 3D response surface plots.
The individual main effects of A, B and C on entrapment efficiency are as shown in Fig. 5. It is found that all the
variables are having interactive effects for the response Y2. The 3D response surfaces and the 2D contour plots of the
response Y2 are shown in Figs. 6–8 and to depict the interactive effects of independent variables on response Y2, one
variable was kept constant while the other two variables varied in a certain range. The shapes of response surfaces and
Fig. 8. Cubic design presenting the interaction between the Polymer and Sonication time and sonication frequency affecting the Entrapment efficiency.
Fig. 9. Perturbation plot showing the main effect of Polymer concentration (A), Sonication frequency (B) and sonication time (C) on Practical yield (Y3).
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89 to 72%. Similarly at high levels of A, Y2 reduced from 86 to 82%. The interaction between A and C on practical yield at a
fixed level of C is shown in Fig. 8 and the interaction between A and B on practical yield at a fixed level of B. At low levels
of A, Y3 reduced from 88.64 to 88.12%. Similarly at high levels of A, Y3 reduced from 88 to 78%. After generating the
polynomial equations relating the dependent and independent variables, the process was optimized for the responses
(Fig. 9). Numerical optimization using the desirability approach was employed to locate the optimal settings of the
process variables to obtain the desired responses (Figs. 10–12). Optimized conditions were obtained by setting constraints
on the dependent and independent variables. Optimization was performed to obtain the levels of A-C which maximize Y1,
Y2 and Y3. The optimized levels and predicted values of Y1, Y2 and Y3 are shown in Table 6.
Based on the factorial design studies, the optimized formulation of Isradipine nanoparticle was founded in Table 6. The
optimized formula showed better particle size, entrapment efficiency and practical yield i. e. 343 nm and 83% and 85% re-
spectively. To verify these values, three batches of nanoparticle was prepared according to the predicted level of A, B and C.
obtained Y1, Y2 and Y3 values were in a closed agreement with the predicted values as shown in Table 2. This demonstrated the
reliability of optimized procedure in predicting the operating parameters for the preparation of isradipine nanoparticle. The
selected formulation was subjected to invitro release studies.
Fig. 10. Factorial contour Response surface plot presenting the interaction between the Polymer and Sonication time affecting the Practical yield at
constant sonication frequency.
Fig. 11. Response surface plot presenting the interaction between the Polymer and Sonication time affecting the Practical yield at constant sonication
frequency.
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The isradipine nanoparticles were prepared by solvent evaporation method with PMMA as biodegradable polymers. This
method was comparatively easy to prepare than other methods. During the preparation of nanoparticle, the aqueous and
organic phase was emulsified completely to form spherical shaped particles. The stability was provided by quasi-emulsifier.
Fig. 12. Cubic design presenting the interaction between the Polymer and Sonication time and sonication frequency affecting the Practical yield.
Table 6
Optimized isradipine nanoparticle values obtained by the constraints applies on Y1, Y2 and Y3.
Independent variables Values Predicted values Observed values
Globule size (Y1) EE (Y2) Practical Yield (Y3) Globule size (Y1) EE (Y2) Practical Yield (Y3)
Polymer 750.00 343.14 83.74 85.39 346.2 84.32 84.94
Sonication time 37.50
Sonication Frequency 40.00
Fig. 13. SEM image of Isradipine nanoparticle.
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Fig. 14. FTIR Spectrum of pure Isradipine.
Fig. 15. FTIR Spectrum of Isradipine nanoparticle.
Fig. 16. Typical chromatogram of isradipine standard.
Fig. 17. Invitro drug release of Isradipine nanoparticle.
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Table 7
Pharmacokinetics Parameters of isradipine nanoparticle.
S. no. Parameters Isradipine solution (oral) Isradipine nanoparticle
1 Cmax (ng/mL) 702 1502
2 Tmax (h) 0.25 0.5
3 T1/2 (h) 4.81 150.54
4 AUC (ng/mL h) 3919.87 10011.75
5 AUMC (ng/mL h2) 30315.61 40230737.71
6 MRT (h) 6.6 217.12
7 Clearances ((ng/mL)/h) 0.002 6.74
AUC – Area under curve, AUMC – Area under moment curve, MRT – Mean residential time.
Fig. 18. In-vivo antihypertensive studies of isradipine nanoparticles.
Fig. 19. Plasma concentration of isradipine nanoparticles.
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The nanoparticles were dried by freeze dryer at 20 °C for 26 h to get free flowing power of drug loaded nanoparticles. The
dried nanoparticle was stored in freeze condition for further studies. The optimized formulation of nanoparticles showed
smooth and spherical shape (Fig. 13). These shape was produced by fully saturated of polymer and the diffusion rate of
solvent was minimal, leading to formation of smooth, spherical and homogeneously distributed particles, which has smooth
surface and the solvent was completely removal from the nanoparticles.
The FTIR studies showed (Figs. 14 and15) that the significant peaks of isradipine are C N stretching at 1226 cm1, C-O
vibration at 1648 cm1, N-H at 3439 cm1, O H vibration at 3626 cm-1 and C¼C vibration at 3244 cm1. Finally the FTIR
studies of mixture of polymers and drug does not show any significant change. This result indicates that there are no any
interactions between drug and polymers.
The optimized nanoparticle formulation subjected to in-vitro drug release study using pH 7.4 phosphate buffers and the
isradipine was analyzed by RP-HPLC at 325 nm (Fig. 16). The drug release was initially bust followed by sustained release.
Initially 2.8% drug release at 30 min and sustained release of 73% at 24th h (Fig. 16). The initial bust release was produced by
surface adhered drug particles and the sustained release due to release from polymeric matrix (Fig. 17).
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Administration of empty PMMA nanoparticle had no significant effect on systolic arterial blood pressure. After oral
administration of the isradipine solution, systolic arterial blood pressure fell very rapidly from 19573 mmHg to
10572 mmHg at 0.25 h, and then returned rapidly to a value not significantly different from the pre-injection value
(19373 mmHg) at 12 h. After administration of isradipine nanoparticles, systolic arterial blood pressure fell gradually and
the maximal antihypertensive effect (15272 mmHg) was obtained at 1 h. At 10 h the systolic arterial blood pressure in the
PMMA group (170þ3 mmHg) was no different from that point (Fig. 18).
Blood pressure initially fell to a value less than the lower limit of cerebral blood flow autoregulation for approximately
15 min, extending these data to human, daily repetition of such periods of iatrogenic cerebral ischaemia over several years
could have a very detrimental effect on brain functions. With the PMMA nanoparticle preparation the fall in blood pressure
was delayed and the nadir reached (at 1 h) 15272 mmHg was well above the value for the lower limit of cerebral blood
flow autoregulation. The polymer loaded isradipine nanoparticle were sustained the drug release form the matrix, these
leads to optimized control of hypertensive action.
Based on plasma concentration time profile (Fig. 19), pharmacokinetic parameters were calculated by using PK solver
software. The pharmacokinetics parameters Cmax, Tmax, AUC, AUMC, MRT, t1/2 and clearances of isradipine solution (oral)
were 702 ng/mL, 2 h, 0.25 h, 3919.87 ng/mL h, 30315.61 ng/mL h2, 4.8 h and 0.002 ng/mL/h respectively. In case of isradipine
nanoparticle formulation showed 1502 ng/mL, 0.5 h, 10011.75 ng/mL h, 40230737.7 ng/mL h2, 217.1 h and 6.7 ng/mL/h, re-
spectively (Table 7). These pharmacokinetics values indicated that, isradipine concentration was significantly maintained
throughout the time period. Isradipine nanocarriers shows increased Cmax, mean residence time (MTR), AUC and AUMC.
The increase in Cmax can be explained by the slow diffusion of the drug from the nanoparticles. This may explain the
decrease in the initial antihypertensive effect with the nano forms, especially PMMAwhich showed a plasma level between
2 and 3 times less than that of the isradipine solution. The invivo antihypertensive studies of isradipine nanoparticle shows
effective therapeutics concentration in blood when compare to isradipine pure form.4. Conclusion
In this research we tried isradipine nanoparticle preparation by solvent evaporation method and optimized by 3-level
factorial design studies. From preliminary experiments, the polymer concentration (A), sonication frequency (B) and so-
nication time (C) were identified as the most significant variables which influence the particle size, entrapment efficiency
and practical yield. The quantitative effect of these factors at different levels was predicted by using polynomial equations.
Response surface methodology was then used to predict the optimum levels of these factors to obtain nanoparticles with
uniform particle size and high entrapment efficiency and practical yield. One formulation of nanoparticle was prepared
according to these optimized levels. Observed responses were in close agreement with the predicted values of the optimized
process, thereby demonstrating the feasibility of the optimization procedure for preparation of isradipine nanoparticles. The
factorial design provides a unique opportunity for the large-scale preparation of isradipine nanoparticle with uniform particle
size distribution with high entrapment efficiency and practical yield. The in vivo antihypertensive studies of isradipine na-
noparticle shows effective therapeutics concentration in blood when compare to isradipine pure form. Based on pharma-
cokinetic assessment, isradipine nanoparticle shows effective therapeutic concentration compare with pure solution form.Acknowledgment
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